Roy Buchanan
Stock Analyst at JMP Securities
(4.69)
# 182
Out of 5,026 analysts
71
Total ratings
56.52%
Success rate
49.38%
Average return
Main Sectors:
Stocks Rated by Roy Buchanan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CDTX Cidara Therapeutics | Maintains: Market Outperform | $153 → $173 | $105.62 | +63.79% | 8 | Oct 3, 2025 | |
| ASMB Assembly Biosciences | Initiates: Market Outperform | $38 | $28.44 | +33.61% | 1 | Sep 24, 2025 | |
| DVAX Dynavax Technologies | Reiterates: Market Outperform | $32 | $9.93 | +222.26% | 8 | Aug 22, 2025 | |
| ENTA Enanta Pharmaceuticals | Maintains: Market Outperform | $24 → $25 | $11.65 | +114.54% | 15 | Aug 12, 2025 | |
| PYPD PolyPid | Maintains: Market Outperform | $16 → $14 | $3.35 | +318.54% | 2 | Jun 17, 2025 | |
| CVAC CureVac | Reiterates: Market Outperform | $10 | $5.40 | +85.19% | 9 | May 28, 2025 | |
| ANTX AN2 Therapeutics | Maintains: Market Outperform | $5 → $2 | $1.24 | +61.94% | 9 | May 5, 2025 | |
| INO Inovio Pharmaceuticals | Reiterates: Market Outperform | $18 | $2.54 | +608.66% | 3 | Mar 14, 2025 | |
| TPG TPG Inc. | Reiterates: Market Perform | n/a | $57.15 | - | 1 | Feb 13, 2025 | |
| ESPR Esperion Therapeutics | Reiterates: Market Outperform | $7 → $4 | $2.52 | +58.73% | 3 | Feb 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $23 → $14 | $1.61 | +769.57% | 1 | Jan 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $33 | $95.61 | -65.48% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $4 → $5 | $4.47 | +11.86% | 5 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $443 → $448 | $815.61 | -45.07% | 2 | Mar 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Perform | $14 → $16 | $10.61 | +50.80% | 1 | Mar 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.85 | - | 2 | Feb 16, 2023 |
Cidara Therapeutics
Oct 3, 2025
Maintains: Market Outperform
Price Target: $153 → $173
Current: $105.62
Upside: +63.79%
Assembly Biosciences
Sep 24, 2025
Initiates: Market Outperform
Price Target: $38
Current: $28.44
Upside: +33.61%
Dynavax Technologies
Aug 22, 2025
Reiterates: Market Outperform
Price Target: $32
Current: $9.93
Upside: +222.26%
Enanta Pharmaceuticals
Aug 12, 2025
Maintains: Market Outperform
Price Target: $24 → $25
Current: $11.65
Upside: +114.54%
PolyPid
Jun 17, 2025
Maintains: Market Outperform
Price Target: $16 → $14
Current: $3.35
Upside: +318.54%
CureVac
May 28, 2025
Reiterates: Market Outperform
Price Target: $10
Current: $5.40
Upside: +85.19%
AN2 Therapeutics
May 5, 2025
Maintains: Market Outperform
Price Target: $5 → $2
Current: $1.24
Upside: +61.94%
Inovio Pharmaceuticals
Mar 14, 2025
Reiterates: Market Outperform
Price Target: $18
Current: $2.54
Upside: +608.66%
TPG Inc.
Feb 13, 2025
Reiterates: Market Perform
Price Target: n/a
Current: $57.15
Upside: -
Esperion Therapeutics
Feb 11, 2025
Reiterates: Market Outperform
Price Target: $7 → $4
Current: $2.52
Upside: +58.73%
Jan 30, 2025
Maintains: Market Outperform
Price Target: $23 → $14
Current: $1.61
Upside: +769.57%
Jan 10, 2025
Reiterates: Market Outperform
Price Target: $33
Current: $95.61
Upside: -65.48%
Aug 2, 2024
Maintains: Market Outperform
Price Target: $4 → $5
Current: $4.47
Upside: +11.86%
Mar 3, 2023
Maintains: Market Outperform
Price Target: $443 → $448
Current: $815.61
Upside: -45.07%
Mar 1, 2023
Maintains: Market Perform
Price Target: $14 → $16
Current: $10.61
Upside: +50.80%
Feb 16, 2023
Downgrades: Market Perform
Price Target: n/a
Current: $0.85
Upside: -